The Thousand Oaks-based biotech giant hit it big when the Food and Drug Administration approved revolutionary multiple myeloma drug Kyprolis for treatments with Kyprolis in combination with another ...
NICE has rejected Amgen’s Kyprolis in second line multiple myeloma treatment in first draft guidance, citing uncertainties over long-term survival benefits. The cost-effectiveness body is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback